Free Trial
NASDAQ:DTIL

Precision BioSciences Q1 2026 Earnings Results & Report

Precision BioSciences logo
$7.57 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$7.58 +0.00 (+0.07%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precision BioSciences missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 5, 2026. The company reported EPS of -$0.75 versus the -$0.6550 consensus estimate, while revenue of $10.84 million topped the $4.05 million estimate by $6.79 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Precision BioSciences EPS Results

Actual EPS
-$0.75
Consensus EPS
-$0.6550
Beat/Miss
Missed by -$0.0950
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Precision BioSciences Revenue Results

Actual Revenue
$10.84 million
Expected Revenue
$4.05 million
Beat/Miss
Beat by +$6.79 million
YoY Revenue Growth
N/A

Precision BioSciences Q1 2026 Earnings FAQ

Precision BioSciences (NASDAQ:DTIL) reported earnings of -$0.75 per share for Q1 2026, missing the consensus estimate of -$0.6550. The report was announced on Tuesday, May 5, 2026.

Precision BioSciences reported revenue of $10.84 million for Q1 2026, against a consensus estimate of $4.05 million.

Precision BioSciences Earnings Headlines

HC Wainwright Has Bullish Estimate for DTIL FY2026 Earnings
Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.tc pixel
See More Precision BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email.

About Precision BioSciences

Precision BioSciences (NASDAQ:DTIL) is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases.

The company’s programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments.

Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences has also pursued applications of its gene-editing technology through collaborations and licensing arrangements.

View Precision BioSciences Profile